中国药业2024，Vol.33Issue(2)：113-116,4.DOI:10.3969/j.issn.1006-4931.2024.02.028
仿制与原研注射用头孢曲松钠治疗社区获得性肺炎患儿药物经济学比较
Pharmacoeconomic Comparison of Generic and Original-Patented Ceftriaxone Sodium for Injection in the Treatment of Community-Acquired Pneumonia in Children
摘要
Abstract
Objective To compare the pharmacoeconomics of bid-wining Ceftriaxone Sodium for Injection in the National Centralized-Drug Procurement(generic drug)and corresponding original-patented drug in the treatment of community-acquired pneumonia(CAP)in children.Methods A total of 292 children(three months to fourteen years)with non-severe CAP admitted to the Department of Pediatrics in the General Hospital of Xinjiang Military Region from January 2020 to August 2022 were selected by the hospital electronic medical-record system and divided into the group A(140 cases)and group B(152 cases)based on the different therapeutic drugs.The children in the groups A and B were given the intravenous drip of generic and original-patented drug(both with a specification of 1.0 g each)respectively.The clinical efficacy and incidence of adverse reactions in the two groups were obtained,and the treatment costs were calculated.The cost-effectiveness analysis was used to compare the pharmacoeconomics,and the sensitivity analysis was used for verification.Results The effective rates in the groups A and B were similar(87.14%vs.89.47%,P>0.05).The treatment costs(excluding hospitalization costs)in the group A were significantly lower than those in the group B(P<0.01).The time to temperature improvement in the group A was significantly longer than that in the group B,and the incidence of adverse reactions was significantly higher than that in the group B(P<0.05).The incremental cost-effectiveness ratio(ICER)in the group B was 471.36.The sensitivity analysis showed that the ICER in the group B was 424.23 when the total costs decreased by 10%,and that was 364.88 when the effective rate was at the lower limit of the 95%CI.Conclusion The generic Ceftriaxone Sodium for Injection is more economical than original-patented drug.关键词
儿童/社区获得性肺炎/注射用头孢曲松钠/原研药/仿制药/药物经济学/成本-效果Key words
child/community-acquired pneumonia/Ceftriaxone Sodium for Injection/original-patented drug/generic drug/pharmacoeconomics/cost-effectiveness分类
医药卫生引用本文复制引用
李雨萱,尹东锋,李倩..仿制与原研注射用头孢曲松钠治疗社区获得性肺炎患儿药物经济学比较[J].中国药业,2024,33(2):113-116,4.基金项目
军队后勤科研项目[ZLJ22J022]. （）
